The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…
Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers…